Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I
Man, now that drop was predictable.
I'm waiting until after cc. Will be interesting. Why? Because if Missling doesn't reassure the market and a lot of time passes between now and the commencement of the first trial, I'm afraid we'll see 2s again.
What I don't get is the 3-trial promise when it was probably evident it wasn't going to happen. Like most things Anavex, IR probably didn't even know what the hell was going on in clinical development. Sad!
Anavex will host a conference call at 4:30 p.m. ET today, December 11, 2017.
Hey, guys, it's the perfect time to call in to express your disappointment. Over the past few weeks/months IR assured members Anavex was on track with the commencement of three trials eoy. And if I read sentiment correctly, most of you believed it. Or--don't tell me--you have moved the goal posts again?
Btw, I have seen this multiple times in nanocap biotech companies like Anavex. They will make promises after promises; meanwhile, time ticks, and money dwindles.
Suppose not. But I, for one, am not happy with the news. A pattern developing here. I remember Missling and the imminent data. Imminent PK/PD data. Imminent trials. Time is money.
Will surely hit my 3.30 buy target. Actually, my target has been revised down to 3.00--.75 pre-split!
TNBC final data collection date for primary outcome measure is December 2017. Final complete data June 2018. 25 patients.
Why? They've done nothing for so long any buzz there was is a deafening silence.
clowns, jeff.
TNBC data is overdue, isn't it?
read about these guys. Not a company you want to be associated with. Stock has been in the tank for months on end.
I'm waiting for 3.30 before buying. Will it get there? Let's just put it this way: the closer we get to no news, the further we get from 4.
10% more and it hits my 3.30 target. I wait, patiently.
I hope Missling doesn't have to eat his words: three trials in by eoy.
tell me, guys, this isn't frustrating.
Independent of your investment decision, your input on this board is invaluable. Keep up the good work.
3? Easy. Will trials start? Two board members apparently have confirmation from IR. Let's see.
i'm referring to what everybody else already knows: the placebo effect is real. Period. And when a clinical trial has no placebo arm it's fair to ask: how do we know efficacy was due to medicine? So obvious. So factual. I thought the article was very convincing. Let's run a large trial and find out if the super-responders are super, or if they just think they are.
and if you still don't think the placebo effect could play a part...
https://medium.com/the-mission/the-worlds-most-essential-drug-f8f5eba8407b
Actually, you can't know. In the May 2017 CT, it says: "Additional details of the collaboration were not disclosed." Just curious: do you have the additional details?
Someone on Stocktwits said it wasn't "complicated," and included initial May, 2017 agreement, saying trial agreement details omitted.
Doesn't help much. What was omitted? And why CTO now? Much ado about nothing?
https://www.sec.gov/Archives/edgar/data/1444307/000149315217013893/ex10-11.htm
now that's interesting. Have they filed them much? They usually deal with financials, as you know.
In six months, from 6.25 to 3.81. There are plenty of shares to buy.
agreed.
I mean, I'm not really saying it; the share price is. And if nothing happens, if there's no trial news, from here until the end of the year, without a doubt it will be lower, however briefly.
Means bunk. People are selling. Was 6.25 in May. Now it's 3.81.
I don't think the Street agrees with you.
I find it--amazing--that someone would think, after the price keeps dropping, that shorts are having a hard time covering, that is, if they even want to.
frankly, that's a bet I would not make.
Pretty simple. Whatever's going to happen, it's better if it happens when I buy at 3.40 than at 3.73.